www.bethelfinance.com
Bethel Finance news:
Teva Pharmaceutical Industries Ltd. predicted its earnings and sales would rise in 2012, aided by the introduction of new generic drugs that could help its U.S. business recover from recent weakness.
The Israel generic-drug company, which has diversified into brand-name and over-the-counter drugs, also said its board authorized the repurchase of up to $3 billion of its ordinary shares or American depositary shares from time to time, based on market conditions. The buyback would represent about 8% of Teva's shares outstanding.
No comments:
Post a Comment